Case Study / Evidence & Access

Global HTA evidence programme: Lupus Nephritis

Preparing a specialty product for a crowded US market. Payer and physician research, a price-access modelling tool and an advisory board, distilled into one launch strategy.

Created - Thursday, September 17, 2026

Challenge

A global client needed HTA-ready evidence for a new Lupus Nephritis treatment but faced limited recent HTA experience, an effectively rare disease with off-label comparators, and no precedent for economic modelling in the therapy area.

Solution

We delivered a flexible, workstream-based programme of adaptable global resources, including systematic literature reviews, network meta-analyses, cost-effectiveness and budget-impact models, and a core value dossier, then adapted them into NICE, SMC and NCPE submissions with full pre- and post-submission support.

Outcome

Delivered the full programme and secured the client’s first-ever HTA success, with continuous support then requested across additional countries.

Working on something similar?

Working in partnership with our clients, we embrace our different perspectives and strengths to deliver fresh thinking and solutions that make a difference.

For information about OPEN Health’s services and how we could support you, please get in touch.

Talk to us